Trastuzumab s . c . beim HER 2-positiven Mamma-karzinom – Evidenz und Erfahrungen aus der praktischen Anwendung in 7 deutschen Zentren Subcutaneous Trastuzumab for HER 2-positive Breast Cancer – Evidence and Practical Experience in 7 German Centers
暂无分享,去创建一个
H. Tesch | C. Jackisch | V. Müller | P. Dall | B. Ataseven | S. Seiler | R. Neumeister | T-W. Park-Simon | A. Ruf-Dördelmann
[1] J. Ahn,et al. Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC). , 2015 .
[2] B. Melichar,et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] L. Zelek,et al. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] E. Winer,et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Brewster,et al. Use of a Population Pharmacokinetic Approach for the Clinical Development of a Fixed-Dose Subcutaneous Formulation of Trastuzumab , 2014, CPT: pharmacometrics & systems pharmacology.
[6] Eld,et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) , 2014, Breast.
[7] F. Cardoso,et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] N. Hauser,et al. Manual injection of subcutaneous trastuzumab vs intravenous infusion for HER2-positive early breast cancer: a time-and-motion study , 2013 .
[9] L. Fallowfield,et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. , 2013, The Lancet. Oncology.
[10] V. Harvey,et al. Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer. , 2013, Journal of clinical pharmacology.
[11] Sung-Bae Kim,et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. , 2012, The Lancet. Oncology.
[12] G. Frost. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration , 2007, Expert opinion on drug delivery.
[13] J S Patton,et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. , 2006, Journal of controlled release : official journal of the Controlled Release Society.